Clinical Trial

Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia

Study acronym: MATCH-Treg
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is a multicentric, interventional study that evaluates the efficacy of allogeneic HLA-matched allo-HSCT consisting of myeloablative conditioning coupled with donor Treg/Tcon adoptive immunotherapy for high-risk AML patients.
Trial Details
NCT Number NCT07552649
Lead Sponsor Antonio Pierini
Conditions AML (Acute Myeloid Leukemia)
Enrollment 28 participants
Start Date 2026-04
Primary Completion 2028-04 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-27